文献速递先天性心脏病外科

Norwood心脏手术中辅助自体脐带血干细胞治疗的安全性与可行性

Safety and feasibility of adjunct autologous cord blood stem cell therapy during the Norwood heart operation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-07-30

这项I期开放标签安全性与可行性试验在产前诊断左心发育不良综合征(HLHS)的新生儿中,于Norwood手术期间通过新型含血心脏停搏液冠状动脉内输注技术给予自体脐带血单核细胞(CBMNCs)。13例招募患者中10例接受治疗,未发现与CBMNC治疗相关的严重不良事件;心脏磁共振显示右室射血分数和 indexed 每搏输出量优于匹配历史队列,但作者指出需进一步研究。

要点

  • 13例产前诊断HLHS新生儿中10例接受自体CBMNCs输注,剂量644.9±134×10^6个CBMNCs。
  • 36例次严重不良事件中无一与CBMNC治疗相关,但3例死亡(30%)发生在间歇期第7、25、62天。
  • 心脏磁共振显示右室射血分数66.2±4.5% vs 历史队列53.5±11.6%,indexed每搏输出量47.4±6.2 mL/m2 vs 37.2±10.3 mL/m2。

核心结论

  • 在Norwood手术后第2至3天,通过新型冠状动脉内输注技术在心脏停搏下输注大量未经冷冻保存的自体CBMNCs是可行且安全的。

研究设计与样本

  • I期开放标签安全性与可行性试验,纳入产前诊断HLHS的新生儿,13例招募,10例接受治疗。
  • CBMNCs按NetCord-FACT国际标准处理,未从CBMNCs中分离CBSCs以最大化产量,4°C保存(未冷冻)并在3天内使用。
  • 每次心脏停搏剂量后输注(4×15 mL)。

主要发现

  • 10例患者接受644.9±134×10^6个CBMNCs,其中CD34+ CBSCs为1.5±1.1×10^6个。
  • 间歇期死亡率为30%(n=3,分别在第7、25、62天)。
  • 36例次严重不良事件中无一与CBMNC治疗相关,53%的严重不良事件与3例死亡相关。
  • 2期手术前心脏磁共振(n=5)显示右室质量指数与精确匹配历史队列(n=22)相当;右室射血分数为66.2±4.5% vs 历史队列53.5±11.6%,indexed每搏输出量为47.4±6.2 mL/m2 vs 37.2±10.3 mL/m2。
  • 7例存活者均完成2期手术,右室功能正常(6例三尖瓣反流≤轻度,1例中度)。

临床怎么用

  • 作者认为,在Norwood手术后第2至3天通过新型冠状动脉内输注技术输注大量未经冷冻保存的自体CBMNCs是可行且安全的。

局限性

  • 原文未报告局限性;但结论指出该试验为I期开放标签安全性与可行性试验,样本量小(10例接受治疗),心脏磁共振仅5例,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted this phase I, open-label safety and feasibility trial of autologous cord blood (CB) stem cell (CBSC) therapy via a novel blood cardioplegia-based intracoronary infusion technique during the Norwood procedure in neonates with an antenatal diagnosis of hypoplastic left heart syndrome (HLHS). CBSC therapy may support early cardiac remodeling with enhancement of right ventricle (RV) function during the critical interstage period. METHODS: Clinical grade CB mononucleated cells (CBMNCs) were processed to NetCord-FACT International Standards. To maximize yield, CBSCs were not isolated from CBMNCs. CBMNCs were stored at 4 °C (no cryopreservation) for use within 3 days and delivered after each cardioplegia dose (4 × 15 mL). RESULTS: Of 16 patients with antenatal diagnosis, 13 were recruited; of these 13 patients, 3 were not treated due to placental abruption (n = 1) or conditions delaying the Norwood for >4 days (n = 2) and 10 received 644.9 ± 134 × 106 CBMNCs, representing 1.5 ± 1.1 × 106 (CD34+) CBSCs. Interstage mortality was 30% (n = 3; on days 7, 25, and 62). None of the 36 serious adverse events (53% linked to 3 deaths) were related to CBMNC therapy. Cardiac magnetic resonance imaging before stage 2 (n = 5) found an RV mass index comparable to that in an exact-matched historical cohort (n = 22), with a mean RV ejection fraction of 66.2 ± 4.5% and mean indexed stroke volume of 47.4 ± 6.2 mL/m2 versus 53.5 ± 11.6% and 37.2 ± 10.3 mL/m2, respectively. All 7 survivors completed stage 2 and are alive with normal RV function (6 with ≤mild and 1 with moderate tricuspid regurgitation). CONCLUSIONS: This trial demonstrated that autologous CBMNCs delivered in large numbers without prior cryopreservation via a novel intracoronary infusion technique at cardioplegic arrest during Norwood palliation on days 2 to 3 of life is feasible and safe.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Brizard CP, Elwood NJ, Kowalski R, et al. Safety and feasibility of adjunct autologous cord blood stem cell therapy during the Norwood heart operation. J Thorac Cardiovasc Surg. 2023. PMID: 37527726. doi:10.1016/j.jtcvs.2023.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。